ALIMENTARY TRACT: CLINICAL REVIEW Cyclo-Oxygenase Inhibition in Colorectal Adenomas and Cancer

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• [Cyclooxygenase 2 and carcinogenesis].

  2004cited by this paper
• The Contributions of Cyclooxygenase-2 to Tumor Angiogenesis

  2004cited by this paper
• A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells.

  2003cited by this paper
• Aspirin potently inhibits oxidative DNA strand breaks: implications for cancer chemoprevention.

  2002cited by this paper
• PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells.

  2002cited by this paper
• Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents.

  2002cited by this paper
• Inhibitory effect of a selective cyclooxygenase‐2 inhibitor on liver metastasis of colon cancer

  2002cited by this paper
• Primary chemoprevention of familial adenomatous polyposis with sulindac

  2002cited by this paper
• A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis

  2002cited by this paper
• Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.

  2002cited by this paper
• Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer.

  2002cited by this paper
• Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth.

  2002cited by this paper
• Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.

  2002cited by this paper
• Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents.

  2002cited by this paper
• The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease.

  2001cited by this paper
• Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.

  2001cited by this paper
• Cyclooxygenase‐independent actions of cyclooxygenase inhibitors

  2001cited by this paper
• NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis.

  2001cited by this paper
• Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo.

  2001cited by this paper
• Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.

  2001cited by this paper
• Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2

  2001cited by this paper
• Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

  2000cited by this paper
• The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.

  2000cited by this paper
• IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells

  2000cited by this paper
• Long‐term treatment with sulindac in familial adenomatous polyposis: Is there an actual efficacy in prevention of rectal cancer?

  2000cited by this paper
• Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis.

  2000cited by this paper
• From bench to clinic with apoptosis-based therapeutic agents

  2000cited by this paper
• Review article: the stages of gastrointestinal carcinogenesis – application of rodent models to human disease

  2000cited by this paper
• Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer.

  2000cited by this paper
• Transforming Growth Factor-β1 Enhances Ha-ras-induced Expression of Cyclooxygenase-2 in Intestinal Epithelial Cells via Stabilization of mRNA*

  2000cited by this paper
• Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor.

  2000cited by this paper
• Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

  2000cited by this paper
• Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme.

  1999cited by this paper
• Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers.

  1999cited by this paper
• Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis.

  1999cited by this paper
• Non steroidal anti-inflammatory drugs and colorectal cancer: is there a way forward?

  1999cited by this paper
• Antioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF-kappaB activation, and TNF-alpha production.

  1999cited by this paper
• Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing

  1999cited by this paper
• Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac

  1999cited by this paper
• Cyclooxygenase-2 inhibitors in tumorigenesis (part I).

  1998cited by this paper
• Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents

  1998cited by this paper
• Rectal cancer after sulindac therapy for a sporadic adenomatous colonic polyp

  1998cited by this paper
• BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death.

  1998cited by this paper
• Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas.

  1998cited by this paper
• BAD partly reverses paclitaxel resistance in human ovarian cancer cells

  1998cited by this paper
• Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.

  1997cited by this paper
• Effects of sulindac on sporadic colorectal adenomatous polyps.

  1997cited by this paper
• R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer.

  1997cited by this paper
• Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta.

  1997cited by this paper
• Patterns and Emerging Mechanisms Review of the Angiogenic Switch during Tumorigenesis

  1996cited by this paper
• Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac.

  1995cited by this paper
• Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer.

  1995cited by this paper
• Expression of cyclooxygenase-1 and -2 in human colorectal cancer.

  1995cited by this paper
• Effect of sulindac on sporadic colonic polyps.

  1995cited by this paper
• 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma.

  1995cited by this paper
• Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis.

  1995cited by this paper
• Familial adenomatous polyposis (FAP): Frequency, penetrance, and mutation rate

  1994cited by this paper
• Apoptosis in cancer therapy: crossing the threshold.

  1994cited by this paper
• NSAID effect on sporadic colon polyps.

  1993cited by this paper
• Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.

  1993cited by this paper
• Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene.

  1992cited by this paper
• cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase.

  1992cited by this paper
• Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide.

  1992cited by this paper
• Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing.

  1991cited by this paper
• Dependence of indomethacin-induced potentiation of murine tumor radioresponse on tumor host immunocompetence.

  1990cited by this paper
• Increase in radioresponse of murine tumors by treatment with indomethacin.

  1988cited by this paper

• Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial

  2021cites this paper
• Immature Myeloid Cells Promote Tumor Formation Via Non-Suppressive Mechanism

  2014cites this paper
• Nonsteroidal anti-inflammatory drug sulindac sulfide suppresses structural protein Nesprin-2 expression in colorectal cancer cells.

  2014cites this paper
• Colon Cancer Vaccines : An Update

  2010cites this paper
• NEOADJUVANT CHEMO RADIATION WITH CAPCITABINE AND CELECOXIB IN STAGE II AND III RECTAL ADENOCARCINOMA

  2010cites this paper
• Review. Colon cancer vaccines: an update.

  2010cites this paper
• MOLECULAR MECHANISMS FOR REGULATION OF GENE EXPRESSION BY LYSOPHOSPHATIDIC ACID IN OVARIAN CARCINOMA CELLS

  2009cites this paper
• VE-cadhérine dans l'inflammation et le cancer: phosphorylation et clivage

  2009cites this paper
• Metalloproteinase-1, metalloproteinase-7, and p53 immunoexpression and their correlation with clinicopathological prognostic factors in colorectal adenocarcinoma.

  2009cites this paper
• Metalloproteinase-1, Metalloproteinase-7, and p53 Immunoexpression and their Correlation with Clinicopathological Prognostic Factors in Colorectal Adenocarcinoma

  2009cites this paper
• Roles of Sonographers in the Management of Diabetes A Proposed Framework

  2008cites this paper
• Celecoxib Treatment Alters the Gene Expression Profile of Normal Colonic Mucosa

  2006cites this paper
• Review article: immune suppression and colorectal cancer

  2006cites this paper
• Chemopreventive potential of diallylsulfide, lycopene and theaflavin during chemically induced colon carcinogenesis in rat colon through modulation of cyclooxygenase-2 and inducible nitric oxide synthase pathways

  2006cites this paper
• Low-Dose Aspirin Does Not Reduce Cancer Incidence in Women Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:47-55.

  2005cites this paper
• Dietary cardamom inhibits the formation of azoxymethane-induced aberrant crypt foci in mice and reduces COX-2 and iNOS expression in the colon.

  2005cites this paper